209 related articles for article (PubMed ID: 19707338)
1. Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease.
Pastores GM
Biologics; 2007 Sep; 1(3):291-300. PubMed ID: 19707338
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.
El Dib R; Gomaa H; Ortiz A; Politei J; Kapoor A; Barreto F
PLoS One; 2017; 12(3):e0173358. PubMed ID: 28296917
[TBL] [Abstract][Full Text] [Related]
4. Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.
Pisani A; Spinelli L; Visciano B; Capuano I; Sabbatini M; Riccio E; Messalli G; Imbriaco M
JIMD Rep; 2013; 9():41-48. PubMed ID: 23430546
[TBL] [Abstract][Full Text] [Related]
5. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
6. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
[TBL] [Abstract][Full Text] [Related]
8. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
9. Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease.
Beck M
Expert Opin Investig Drugs; 2002 Jun; 11(6):851-8. PubMed ID: 12036428
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib RP; Nascimento P; Pastores GM
Cochrane Database Syst Rev; 2013 Feb; (2):CD006663. PubMed ID: 23450571
[TBL] [Abstract][Full Text] [Related]
11. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations.
Caballero L; Climent V; Hernández-Romero D; Quintanilla MA; de la Morena G; Marín F
Curr Med Chem; 2010; 17(16):1679-89. PubMed ID: 20345350
[TBL] [Abstract][Full Text] [Related]
13. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of lymphedema among Anderson-Fabry disease patients: A report from the Fabry registry.
Alkhatib D; Vega JA; Pour-Ghaz I; Al-Taweel O; Khan S; DeCarr K; Bath A; Rawal A; Wilbanks D; Raja J; Butt A; Yedlapati N; Hopkin RJ; Jefferies JL
Mol Genet Metab; 2023 Apr; 138(4):107538. PubMed ID: 36812723
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
17. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib RP; Pastores GM
Cochrane Database Syst Rev; 2010 May; (5):CD006663. PubMed ID: 20464743
[TBL] [Abstract][Full Text] [Related]
19. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
20. Agalsidase alfa for enzyme-replacement therapy in Fabry disease.
Mehta A
Expert Rev Endocrinol Metab; 2010 Sep; 5(5):641-652. PubMed ID: 30764019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
